Phase 1 Mono Clinical Trials
48 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 48 trials
Recruiting
Phase 1
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting
Phase 1Phase 2
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Chronic Myelomonocytic Leukemia (CMML)Myelofibrosis (MF)
M.D. Anderson Cancer Center66 enrolled1 locationNCT07128381
Recruiting
Phase 1
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Chronic Myelomonocytic Leukemia
Huda Salman30 enrolled4 locationsNCT06071624
Recruiting
Phase 1Phase 2
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center75 enrolled1 locationNCT03128034
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety and Tolerability of EP0042
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
Ellipses Pharma70 enrolled6 locationsNCT04581512
Recruiting
Phase 1Phase 2
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Phase 1
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more
Mayo Clinic25 enrolled1 locationNCT05549661
Recruiting
Phase 1Phase 2
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+5 more
PedAL BCU, LLC960 enrolled183 locationsNCT04726241
Recruiting
Phase 1
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative Neoplasm+1 more
Dana-Farber Cancer Institute50 enrolled2 locationsNCT04024761
Recruiting
Phase 1Phase 2
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Aggressive NK-cell LeukemiaLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell Lymphoma+10 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting
Phase 1Phase 2
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center38 enrolled1 locationNCT03896269
Recruiting
Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+26 more
Fred Hutchinson Cancer Center24 enrolled1 locationNCT03326921
Recruiting
Phase 1
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
EBVEpstein-Barr Virus InfectionInfectious Mononucleosis+1 more
National Institute of Allergy and Infectious Diseases (NIAID)750 enrolled1 locationNCT06908096
Recruiting
Phase 1Phase 2
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+11 more
Fred Hutchinson Cancer Center36 enrolled1 locationNCT06928662
Recruiting
Phase 1
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572
Recruiting
Phase 1
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Recurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Myelodysplastic SyndromeRecurrent Juvenile Myelomonocytic Leukemia+3 more
Children's Oncology Group36 enrolled19 locationsNCT06247787
Recruiting
Phase 1Phase 2
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Myelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center58 enrolled1 locationNCT04493138
Recruiting
Phase 1Phase 2
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Acute Myeloid Leukemia+3 more
M.D. Anderson Cancer Center97 enrolled1 locationNCT04140487
Recruiting
Phase 1Phase 2
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Neurofibromatosis 1Leukemia, Juvenile MyelomonocyticJMML+2 more
Therapeutic Advances in Childhood Leukemia Consortium58 enrolled19 locationsNCT05849662